ARTICLE | Clinical News
FDA wants more info on Sunovion Parkinson’s therapy
February 1, 2019 7:54 PM UTC
Sunovion Pharmaceuticals Inc. said late Jan. 30 that FDA issued a complete response letter for its NDA for apomorphine sublingual film (APL-130277) to treat "off" episodes in Parkinson’s disease patients.
The subsidiary of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA requested additional information and analyses, but no new clinical studies are required...
BCIQ Target Profiles